Use of semaphorin-4D binding molecules for treating neurodegenerative disorders
Provided herein are methods for alleviating symptoms in a subject having a neurodegenerative disorder, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D) or to its Plexin-B1 or Plexin-B2 receptors.
1. A method of promoting myelination in a subject having, determined to have, or suspected of having a neuroinflammatory or neurodegenerative disorder, comprising administering to the subject an effective amount of an isolated antibody or antigen-binding fragment thereof which specifically binds to semaphorin-4D (SEMA4D), wherein the antibody or antigen-binding fragment thereof comprises a variable heavy chain (VH) comprising VHCDRs 1-3 comprising SEQ ID NOs 6, 7, and 8, respectively, and a variable light chain (VL) comprising VLCDRs 1-3 comprising SEQ ID NOs 14, 15, and 16, respectively, and wherein the binding to SEMA4D acts to modulate astrocyte-mediated activity of oligodendrocyte-myelin function.
2. The method of claim 1 , wherein the binding molecule modulates astrocyte-mediated synaptic activity, thereby preventing neural cell death.
3. The method of claim 1 , wherein the binding molecule modulates astrocyte-mediated maintenance of the integrity of the blood-brain barrier.
4. The method of claim 1 , wherein the isolated binding molecule specifically binds to the same SEMA4D epitope as a reference monoclonal antibody comprising the heavy chain variable region (VH) amino acid sequence SEQ ID NO: 9 and the light chain variable region (VL) amino acid sequence SEQ ID NO: 10.
5. The method of claim 1 , wherein the isolated binding molecule competitively inhibits a reference monoclonal antibody comprising the heavy chain variable region (VH) amino acid sequence SEQ ID NO: 4 and the light chain variable region (VL) amino acid sequence SEQ ID NO: 10 from binding to SEMA4D.
6. The method of claim 1 , wherein the VH and VL comprise, respectively, SEQ ID NO: 9 and SEQ ID NO: 17 or SEQ ID NO: 10 and SEQ ID NO: 18.
7. The method of claim 1 , wherein the neurodegenerative disorder is selected from a group consisting of Alzheimer's disease, Parkinson's disease, Huntington's disease, Down syndrome, ataxia, amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), HIV-related cognitive impairment, CNS Lupus, mild cognitive impairment, or a combination thereof.
8. The method of claim 1 , wherein the neuroinflammatory disease is Multiple Sclerosis.
9. The method of claim 1 , wherein the subject is human.
10. A method of preventing retraction of astrocyte processes and chemotactic movement of oligodendrocyte precursor cells (OPCs) toward regions of damage in a subject having, determined to have, or suspected of having a neuroinflammatory or neurodegenerative disorder, comprising administering to that subject an effective amount of an isolated antibody or antigen-binding fragment thereof which specifically binds to SEMA4D, wherein the antibody or antigen-binding fragment thereof comprises a variable heavy chain (VH) comprising VHCDRs 1-3 comprising SEQ ID NOs 6, 7, and 8, respectively, and a variable light chain (VL) comprising VLCDRs 1-3 comprising SEQ ID NOs 14, 15, and 16, respectively.
11. The method of claim 10 , wherein the isolated antibody or antigen-bindinng fragment thereof specifically binds to the same SEMA4D epitope as a reference monoclonal antibody comprising the heavy chain variable region (VH) amino acid sequence SEQ ID NO: 9 and the light chain variable region (VL) amino acid sequence SEQ ID NO: 10.
12. The method of claim 10 , wherein the isolated antibody or antigen-bindinng fragment thereof competitively inhibits a reference monoclonal antibody comprising the heavy chain variable region (VH) amino acid sequence SEQ ID NO: 4 and the light chain variable region (VL) amino acid sequence SEQ ID NO: 10 from binding to SEMA4D.
13. The method of claim 10 , wherein the VII and VL comprise, respectively, SEQ ID NO: 9 and SEQ ID NO: 17 or SEQ ID NO: 10 and SEQ ID NO: 18.
14. The method of claim 10 , wherein the neurodegenerative disorder is selected from a group consisting of Alzheimer's disease, Parkinson's disease, Huntington's disease, Down syndrome, ataxia, amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), HIV-related cognitive impairment, CNS Lupus, mild cognitive impairment, or a combination thereof.
15. The method of claim 10 , wherein the subject is human.